Trafalgar Property Group PLC, (AIM: TRAF) was the biggest small-cap riser. We’d love to know why but we don’t have any information.
The company did appoint Dr Paul Francis Challinor to be its executive director. If he was responsible for the 79% share price rise, he will have a lot of work ahead.
Trafalgar described Dr Challinor as an early-stage pioneer and executive manager who is well-respected and respected. He specializes in indoor hydroponic vertical farms and food security.
Wishbone Gold PLC, (AIM: WSBN) saw a 26% increase in its “heritage survey” at the Red Setter Gold-Copper Project 13km southwest of Telfer Gold Mine. It is located in the Patersons Range of Western Australia.
This survey aims to improve access to peripheral targets beyond those that have been cleared. Drilling will begin in the coming weeks. Wishbone stated that the heritage survey will move to the Cottesloe project, 55km south-southwest from the Telfer Gold Mine.
Ncondezi Energy Ltd (AIM: NCCL), formerly known as Oopsidaisy, may be gone. The share price jumped 63% this week due to news about a possible solar and battery project.
Ncondezi board completed an internal review of the Ncondezi 300 Megawatt (MW) power plant in Tete, Mozambique. They believe there is potential for a grid-scale project with solar and battery storage at the site.
Preliminary studies have confirmed that the project site is in favourable solar conditions. Who knew Mozambique could be sunny? – and access the Mozambique grid.
The board is confident that the solar project can be realized without compromising the main power plant.
Immedia Broadcasting Plc (LON: IME), shares jumped 23% to 24.5p after the disposal of Immediate Broadcast Limited, it’s subsidiary. Acquisition PLC has been adopted as the company’s new name, signifying that it is now a cash strap.
DSW Capital PLC (AIM: DSW), a financial advisory firm published its first trading update since December last year. It was a success with the company stating that revenue and adjusted profits before tax for the current fiscal year should be in line with current market expectations.
Tungsten Corp PLC, (AIM: TUNG), the invoice-processing outfit, has been with AIM for almost 10 years. While it hasn’t been a very happy sojourn, shareholders should be relieved of their misery.
The board recommended this week that Pagero accept a 48p share offer. This offer was better than the 40p Kofax had offered.
However, it may not be over as Kofax is still considering its options. Kofax has asked Tungsten Shareholders not to respond to Pagero’s announcement.
Circassia Group PLC, (AIM: CIR), which is a company that develops, markets, and manages medical devices for asthma diagnosis, and management, cheered shareholders with a positive trading statement at the annual general meeting.
The first four months of 2019 saw an increase in clinical revenues by roughly 17% over the same period last year. This was well ahead of management’s expectations. The previous year was slightly behind in research revenues.
The company stated that although we are aware that our business in China (14%) may be affected due to the recent lockdowns in China, it has been trading strongly for the past four months and delivered growth exceeding 23% compared to the same period in 2021.
Sector peers Open Orphan PLC, (AIM: ORPH), which is a rapidly-growing specialist contract research organisation, saw shares rise 5.8% this week after it brought attention to a key considerations paper for developing and manufacturing challenge agents, published in the Wellcome Open Research Journal.
Alex Mann, senior director of clinical and research at Open Orphan subsidiary hVIVO, co-authored the document. It is called “Considerations On The Principles Of Development and Manufacturing Qualities Of Challenge Agents For Use In Infection Models Human”
Wellcome is pleased to support this practical and clear document as a funder of global infectious disease research. This guidance will allow us to harness the potential of human infection research around the globe, providing crucial insights into infectious diseases and allowing us to accelerate the development of vaccines.” Shobana Balasingam is the Wellcome researcher lead for infectious disease prevention.
